Addex Therapeutics reports on Q1 2024 with mixed results By Investing.com – Forex Trader Hub
In their Q1 2024 financial results conference call, Addex Therapeutics (NASDAQ: ADXN) provided updates on their research and development initiatives, financials, and strategic transactions. The company announced progress in their GABAB positive allosteric modulator program, with a candidate expected to be selected for advancement soon. Despite a setback in their epilepsy treatment study, Addex is…